TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device

Dow Jones

09/23

TriSalus Life Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device.

Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year.

The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said.

The company will launch a limited market release of the device in the coming weeks.

"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures," Chief Executive Mary Szela said. "We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients."

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2669273451"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2669273451\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2669273451?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-23 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669273451","market":"other","top_or_hot":-1,"title":"TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLSI\">TriSalus Life</a> Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device. \n</p>\n<p>\n  Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year. \n</p>\n<p>\n  The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said. \n</p>\n<p>\n  The company will launch a limited market release of the device in the coming weeks. \n</p>\n<p>\n  \"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-09-23 04:55</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLSI\">TriSalus Life</a> Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device. \n</p>\n<p>\n  Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year. \n</p>\n<p>\n  The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said. \n</p>\n<p>\n  The company will launch a limited market release of the device in the coming weeks. \n</p>\n<p>\n  \"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2669273451","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669273451","pubTimestamp":1790110500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"TriSalus Life Sciences said it received Food and Drug Administration 510 clearance for a new pressure-enabled drug delivery device.Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year.The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said.The company will launch a limited market release of the device in the coming weeks.\"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","TLSI":"TriSalus Life Sciences Inc.","BK4139":"生物科技"},"translate_title":"TriSalus Life Sciences 的药物输送装置获得 FDA 批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"TLSI":0.9},"content_text":"TriSalus Life Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device. \n\n\n  Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year. \n\n\n  The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said. \n\n\n  The company will launch a limited market release of the device in the coming weeks. \n\n\n  \"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}